ArticleOncoTargets and therapy2013
New dilemmas in small-cell lung cancer TNM clinical staging.
Article in OncoTargets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A nomogram to predict prognosis of small-cell lung cancer patients in stage II based on the ninth edition of the tumor-node-metastasis staging system.Journal of cardiothoracic surgery · 2025Article
- Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.BMJ open · 2023Article
- Tracheal fistula repair with stent placement after failure of reconstruction with muscle tissue. A lung cancer surgery complication.Respiratory medicine case reports · 2021Article
- Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis.Thoracic cancer · 2019Article
- Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease:Journal of Cancer · 2018Article
- Nomogram prediction for the survival of the patients with small cell lung cancer.Journal of thoracic disease · 2017Article
- [Analysis of Efficacy of Surgical Treatment for IIIa Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Article
- Tyrosine Kinase Inhibitors for the Elderly.Journal of Cancer · 2016Review
- Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature.Journal of Cancer · 2016Review
- DDMC-p53 gene therapy with or without cisplatin and microwave ablation.OncoTargets and therapy · 2015Article
- Intensive care unit and lung cancer: when should we intubate?Journal of thoracic disease · 2013Review
- "One-stop shop" spectral imaging for rapid on-site diagnosis of lung cancer: a future concept in nano-oncology.International journal of nanomedicine · 2013Article
- The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis.OncoTargets and therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients with limited disease (LD) behave similarly to those with extensive disease (ED) from a prognostic point of view. On the other hand, a proportion of patients with ED small-cell lung cancer (SCLC) behave similarly to those with LD. PATIENTS AND
methodsIn this retrospective study analysis, 764 patients with proven SCLC were included and managed with the same therapeutic protocols. Of these patients, 278 (36.4%) had LD, while 486 (63.6%) had ED.
resultsNo statistically significant difference was observed for survival for IA and IB disease stages (P = 0.254) and between IIA and IIB stages (P = 0.256) according to the new tumor, node, metastasis (TNM) staging classification classification. In addition, no statistical significant difference was observed for survival between patients with (IIA + IIB) and IIIA (P = 0.951), (IIA + IIIA, P = 0.658), and (IIB + IIIA, P = 0.573) stages. Statistical significant difference was observed for survival among the LD SCLC patients with (IA + IB), (IIA + IIB + IIIA), and IIIB stages (P < 0.001). Similarly, statistical significance was observed for ED SCLC patients with (IIA + IIB + IIIA), IIIB, and IV stages (P < 0.001).
conclusionsAlthough stratification of SCLC patients in LD and ED is generally satisfactory, the TNM staging system is recommended for more detailed prognostic information and treatment evaluation in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.